0001415889-23-008492.txt : 20230522
0001415889-23-008492.hdr.sgml : 20230522
20230522162012
ACCESSION NUMBER: 0001415889-23-008492
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230519
FILED AS OF DATE: 20230522
DATE AS OF CHANGE: 20230522
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cole Douglas G.
CENTRAL INDEX KEY: 0001486373
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39746
FILM NUMBER: 23944690
MAIL ADDRESS:
STREET 1: AVEO PHARMACEUTICALS, INC.
STREET 2: 75 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc.
CENTRAL INDEX KEY: 0001821323
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474005543
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 BINNEY STREET
STREET 2: STE 600
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-336-7540
MAIL ADDRESS:
STREET 1: 100 BINNEY STREET
STREET 2: STE 600
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
form4-05222023_040501.xml
X0407
4
2023-05-19
0001821323
Sigilon Therapeutics, Inc.
SGTX
0001486373
Cole Douglas G.
C/O SIGILON THERAPEUTICS, INC.
100 BINNEY STREET STE 600
CAMBRIDGE
MA
02142
true
false
false
false
0
Stock Option (Right to Buy)
0.6366
2023-05-19
4
A
0
8888
0
A
2033-05-18
Common Stock
8888
8888
D
The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024
/s/ Matthew Kowalsky, Attorney-in-Fact
2023-05-22